These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26852977)

  • 1. Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Penson DF
    J Urol; 2016 Feb; 195(2):353. PubMed ID: 26852977
    [No Abstract]   [Full Text] [Related]  

  • 2. Words of wisdom: Re: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Tombal B
    Eur Urol; 2014 May; 65(5):1013-4. PubMed ID: 24646499
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Mearini L
    Int Braz J Urol; 2014; 40(2):287-8. PubMed ID: 24856502
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
    JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent versus continuous androgen deprivation treatment of prostate cancer.
    Zhu J; Zheng Y
    J Clin Oncol; 2013 Nov; 31(31):4024. PubMed ID: 24062402
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Tombal B
    Eur Urol; 2014 Apr; 65(4):e56. PubMed ID: 24380648
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 8. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intermittent androgen deprivation (IAD) for advanced prostate cancer. Why not the standard of therapy?].
    Prapotnich D; Sánchez-Salas R; Cathelineau X; Stakhovskyi O; Rocha JE; Vallancien G
    Arch Esp Urol; 2009 Nov; 62(9):689-94. PubMed ID: 19955592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
    Park JC; Eisenberger MA
    J Clin Oncol; 2016 Jan; 34(3):211-4. PubMed ID: 26628474
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Kratiras Z; Konstantinidis C; Skriapas K
    Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy.
    Sweeney CJ
    JAMA Oncol; 2015 Dec; 1(9):1270-1. PubMed ID: 26379098
    [No Abstract]   [Full Text] [Related]  

  • 16. Intermittent androgen deprivation therapy: clarity from confusion.
    Klotz L
    Eur Urol; 2013 Nov; 64(5):731-3. PubMed ID: 23866956
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current evidence about intermittent androgenic deprivation in prostate cancer].
    López JD; López-Fontana G; López-Fontana R
    Actas Urol Esp; 2012; 36(10):608-12. PubMed ID: 22728019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer--management of disseminated disease (intermittent androgen suppression).
    Lobel B; Richard F
    Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586
    [No Abstract]   [Full Text] [Related]  

  • 19. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
    Abrahamsson PA
    Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.